Inhibikase Therapeutics, Inc. (IKT) Misses Q2 EPS by 30c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Inhibikase Therapeutics, Inc. (IKT) Misses Q2 EPS by 30c

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

August 14, 2023 4:20 PM EDT

Company to host conference call on Tuesday, August 15, 2023 at 8:00 a.m. ET

BOSTON and ATLANTA, Aug. 14, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for... More